



HAL
open science

Innovations thérapeutiques en hémostase

Rapport Hcéres

► **To cite this version:**

Rapport d'évaluation d'une entité de recherche. Innovations thérapeutiques en hémostase. 2018, Université Paris Descartes, Institut national de la santé et de la recherche médicale - INSERM. hceres-02031618

HAL Id: hceres-02031618

<https://hal-hceres.archives-ouvertes.fr/hceres-02031618v1>

Submitted on 20 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

REPORT ON THE RESEARCH UNIT:
Innovative Therapies in Haemostasis (IThEM)

UNDER THE SUPERVISION OF THE
FOLLOWING INSTITUTIONS AND
RESEARCH BODIES:

Université Paris Descartes
Institut national de la santé et de la recherche
médicale - Inserm

ÉVALUATION CAMPAIGN 2017-2018
GROUP D



In the name of Hcéres¹:

Michel Cosnard, President

In the name of the expert committee²:

Marc Hoylaerts, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

¹ The president of Hcéres "countersigns the evaluation reports set up by the expert committees and signed by their chairman." (Article 8, paragraph 5);

² The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2).

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

UNIT PRESENTATION

| | |
|--------------------------------------|-------------------------------------|
| Unit name: | Innovative Therapies in Haemostasis |
| Unit acronym: | IThEM |
| Requested label: | UMR_S |
| Application type: | Renewal |
| Current number: | UMR_S 1140 |
| Head of the unit (2017-2018): | Ms Pascale GAUSSEM |
| Project leader (2019-2023): | Ms Pascale GAUSSEM |
| Number of teams: | 1 |

COMMITTEE MEMBERS

| | |
|--|---|
| Chair: | Mr Marc HOYLAERTS, KU Leuven, Belgium |
| Experts: | Mr Ramaroson ANDRIANTSITOHAINA, Université d'Angers (representative of Inserm CSS) Mr Denis ANGOUVANT, Université de Tours Mr Jean-Christophe GRIS, Université de Montpellier (representative of CNU) Ms Nathalie JOUY, Université de Lille (supporting personnel) Mr Pierre MANGIN, Université de Strasbourg |
| HCERES scientific officer: | Ms Florence PINET |
| Representatives of supervising institutions and bodies: | Mr Raymond BAZIN, Inserm Mr Jean-Louis BEAUDEUX, Faculté de pharmacie Ms Pascale MARTEL, Inserm Mr Stefano MARULLO, Université Paris Descartes |

INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The unit is located in the faculty of Pharmacy of Paris and headed by Ms Pascale Gaussem. The unit has a long history as it was created in 1995 by Ms Martine Aiach and directed from 2006 until 2010 by Mr Joseph Emmerich. In 2012, Ms Pascale Gaussem was appointed as acting director and the unit was recreated in 2014 as a single team working on three interconnected themes. The restructured unit is focusing on integrating clinical and experimental approaches, fostering integration of basic and translational research. The unit is part of the “Unité mixte de Service CPR2”, with full access to several core facilities, all on the same site.

MANAGEMENT TEAM

The head of the unit is Ms Pascale Gaussem, and the deputy head is Ms Catherine Boisson-Vidal.

HCERES NOMENCLATURE

SVE5_2.

SCIENTIFIC DOMAIN

The team is active in the field of vascular and cellular haemostasis and on the development of new therapeutic approaches. Its activities were subdivided along three axes: 1. Vascular biotherapy; 2. Platelet production and function; 3. Response to antithrombotic agents. Since then, these themes are slightly reorganised along two major axes: Theme 1, Haemostasis, angiogenesis and vascular differentiation; Theme 2, Haemostasis and antithrombotic agents. The projects proposed rely on expertise in stem cell biology (endothelial cell and megakaryocyte progenitors); vascular biology (endothelial cell function in various contexts), hematology (megakaryopoiesis and thrombopoiesis), haemostasis (platelet function, coagulation) and thrombosis (anticoagulants, venous thromboembolism).

UNIT WORKFORCE

| Unit workforce | Number 30/06/2017 | Number 01/01/2019 |
|---|----------------------|----------------------|
| Permanent staff | | |
| Full professors and similar positions | 9 | 10 |
| Assistant professors and similar positions | 2 | 5 |
| Full time research directors (Directeurs de recherche) and similar positions | 4 | 4 |
| Full time research associates (Chargés de recherche) and similar positions | 2 | 2 |
| Other scientists (“Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.”) | 0 | 0 |
| High school teachers | 0 | 0 |
| Supporting personnel (ITAs, BIATSSs and others, notably of EPICs) | 7.5 | 7.5 |

| | | |
|---|-------------|--|
| TOTAL permanent staff | 24.5 | |
| Non-permanent staff | | |
| Non-permanent professors and associate professors, including emeritus | 1 | |
| Non-permanent full time scientists, including emeritus, post-docs | 2 | |
| Non-permanent supporting personnel | 2 | |
| PhD Students | 28 | |
| TOTAL non-permanent staff | 33 | |
| | | |
| TOTAL unit | 57.5 | |

GLOBAL ASSESSMENT OF THE UNIT

The unit has two main themes (Vascular biotherapy and Haemostasis + antithrombotic agents) with basic and clinical researches. The scientific production of the unit was remarkable and of excellent quality. The unit has been extremely active in obtaining national and international grants. Two start-up companies have been created by members of the unit. The unit is highly implicated in teaching and providing a high level of training by research to their numerous PhD students. The next five-year plan aims at deciphering new aspects of haemostasis and angiogenesis. The projects are of great importance in terms of management of patients treated with anti-thrombotic agents and realistic because of the strong interactions between researchers, biologists and physicians in the unit.

The evaluation reports of Hceres
are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions
Evaluation of higher education and research institutions
Evaluation of research
Evaluation of doctoral schools
Evaluation of programmes
Evaluation abroad



2 rue Albert Einstein
75013 Paris, France
T. 33 (0)1 55 55 60 10

hceres.com

[@Hceres_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)